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Abstract. Background/Aim: Chloride intracellular channel 1
(CLIC1) represents a promising target for personalized therapy.
Our aim was to assess CLIC1 expression in clear cell renal cell
carcinoma (cc RCC) and identify its possible prognostic role.
Materials and Methods: Fifty cases of cc RCC were evaluated
and selected for immunohistochemistry. CLIC1 expression was
correlated with tumor grade, invasion and heterogeneity.
Results: A total of 87.5% of the cases were CLIC1 positive, with
either a homogeneous (31.42%) or a heterogeneous (68.57%)
pattern. Low, mild and strong CLIC1 expressing tumors were
defined based on nuclear (N), cytoplasmic (C), membrane (M)
or combinations of them (NC, NM, CM, NCM) in terms of
CLIC1 distribution. A significant correlation was found between
tumor grade and percent of positive tumor cells (p=0.017). For
G3 tumors, CLIC1 cytoplasmic expression was strongly
correlated with high expression status (p=0.025) and tumor
heterogeneity (p=0.004). CLIC1 expression was also correlated
with metastasis (p=0.046). Conclusion: We defined four cc RCC
groups depending on G, CLIC1 expression and pattern: i)
G3/NM/low CLIC1+, ii) G2/CM/mild CLIC1+ iii) G1 or
G2/NM or CM /high CLIC1+, and iv) G2/M /high CLIC1+.
CLIC1 (chloride intracellular channel 1) is a protein that
belongs to the family of ion channels of chlorine. This protein
is naturally expressed in the human body and is involved in
many cellular processes, such as cell volume regulation,
regulation of membrane potential, cell cycle regulation, cell
proliferation and cell differentiation (1). CLIC1 normally exists
as a soluble globular protein, however, in response to oxidative
stress, it translocates from the cytoplasm to the cell membrane
where it selectively acts as a chloride channel (2, 3). A potential
involvement of CLIC1 in tumor development is suspected both
for its role in cell cycle regulation as well as for its functional
expression during oxidative stress.
Amongst the six members of intracellular chloride ion
channel protein family (CLICs), CLIC1 and CLIC4 have been
extensively studied regarding their involvement in tumor
development (4). Indeed, CLIC1 is overexpressed in several
tumor types, such as gastric cancer (5), oral squamous cell
carcinomas (6) or glioblastoma (7). Recently, Barbieri et al.
reported that CLIC1 inhibition induces glioblastoma growth
inhibition, mainly by acting on CLIC1-rich glioblastoma stem
cells, decreasing their proliferation and subsequently tumor
progression (8). Although CLIC1 expression in cancer stem
cells (CSC) has been certified only for glioblastoma (7, 8),
indirect evidence suggests that CLIC1 is also expressed in
tumor stem cells from other aggressive malignancies, such as
pancreatic (9), ovarian (10) and esophageal cancer (11). 
CLIC1 is characterized by a high versatility regarding its
ability to translocate from cytosol to the nucleus and/or the
plasma membrane during malignant transformation (12),
based on its ability to spontaneously convert from soluble to
an integral membrane-bound form. This changeable state is
most probably regulated by the membrane lipid composition,
especially by cholesterol, together with external factors, such
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as oxidation and pH (13, 14), however, a precise mechanism
is currently unknown. Once CLIC1 is incorporated in the
plasma membrane, tumor cells become highly active, with a
rapid proliferation rate (15), increased invasiveness (16) and
metastatic potential (17). 
Kidney cancer accounts for 5% and 3% of all
malignanciens in adult men and women, respectively (18).
The most frequent histological type (around 80%) is
represented by clear cell renal cell carcinoma (cc RCC). Cc
RCC is a kidney malignancy with an unpredictable behaviour,
especially in terms of response to treatment (19). Although in
most cases kidney cancer is diagnosed when already
localized, approximately 20% of patients will develop
metastasis following nephrectomy with curative intent (20).
In other cases, cc RCC is already invasive at the time of
diagnosis and, despite of new targeted therapies, patients
present a high mortality rate (16). This suggests that the
spectrum of cc RCC is not fully characterized regarding its
molecular profile. Unpredictable response to treatment
represents one of the most controversial issues in cc RCC.
Resistance to therapy is based on an incomplete mechanism
of action (21), and there is no effective definitive therapeutic
tool available (22). Lichner et al. recently reported that
Sunitinib therapy for advanced RCC induces selection of a
tumor cells subpopulation able to survive and to grow as
spheroids in tumor models xenografts (23). The group also
showed that these cells express E cadherin as a key
contributor to the survival of RCC cells under Sunitinib
treatment. The Memorial Sloan Kettering Cancer Centre RCC
classification (Motzer criteria) focuses on clinical features of
RCC to predict survival. This system evaluates: i)
performance status, ii) LDH value, iii) haemoglobin value,
iv) serum calcium concentration and v) time from initial
diagnosis to systemic treatment (24); however, no
pathological variables are taken into consideration. A previous
attempt to integrate the clinical data with tissue markers so
as to predict disease mortality in metastatic RCC was done
by Kim et al. (25), which, unfortunately, highlighted the
limitations. Taken together, it is clear that there is the strong
need for novel prognostic biological markers reliably
assessing tumor invasion as well as its metastatic potential in
cc RCC. These tools are also needed for the identification of
patients at higher risk of recurrence following local treatment.
CLIC1 is expressed in the normal kidney in the glomerular
structures and also on the apical domain of proximal tubules’
epithelial cells (26), however, its role of in renal cancer is yet
to be elucidated. The Human Atlas Gene Protein mentions
CLIC1 as an unfavorable prognostic marker in renal cancer,
with no adequate details available on it (https://www.
proteinatlas.org/ENSG00000213719-CLIC1/t). 
Evidence regarding the interrelation and crosstalk between
CLIC1 and RCC tumor cells derive mostly from in vitro and
experimental tumor xenograft studies using different renal cancer
cell lines or tumor cells isolated from patients with localized and
metastatic RCC (15). CLIC1 inhibition seems to decrease tumor
invasion and metastasis due to a blockage of the myosin light
chain kinase (MYLK) and of β3 integrin, suggesting an
important role for CLIC1 in integrin-mediated actomyosin
dynamics in cells with invasive and metastatic potential. 
Despite of clear experimental evidence about the role of
CLIC1 in RCC progression, no data are available about its
expression on human cc RCC specimens at present. Thus,
we aimed to describe CLIC1 expression pattern using
immunohistochemistry on human tumor samples of cc RCC
and to correlate the pattern of reaction with tumor grade,
invasion and tumor heterogeneity.
Materials and Methods
Tumor samples. Fifty cases of cc RCC were collected during open
surgery performed for kidney tumor mass of suspicious or proven
malignant origin. Initial diagnosis was made by imaging (e.g. CT
scan, MRI). Both localized and metastatic diseases were studied.
Informed consent was obtained from all patients before surgery and
all procedures respected ethical principles regarding the use of
human tissue specimens for research purposes, according with
WMA Declaration of Helsinki (https://www.wma.net/policies-
post/wma-declaration-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects/).
Tissue primary processing. Tumor samples fixed for 24 h in 10%
buffered formalin were included in a routine automated workflow
of paraffin embedding by using automated ThermoShandon carousel
for histopathology (ThermoScientific Fischer, Cambridge, UK)
including detailed protocols for each type of tissue. Automatic
workflow follows the routine steps widely known in histopathology
and has as a final product the parraffin block ready for sectioning
Three micrometer-thick serial sections were cut from each specimen
and were stained with haematoxylin and eosin for histopathological
evaluation. 
Immunohistochemistry. Following initial evaluation, additional
paraffin-embedded slides from each RCC case were immunostained
using the monoclonal mouse anti human CLIC1 antibody (Clone
356.1, dilution 1:2,000) (Santa Cruz Biotechnology, Heidelberg,
Germany), incubated at room temperature for 30 min. Incubation
with the primary antibody was followed by the use of Bond Polymer
Refine Detection System (Leica Biosystems, Newcastle Upon Tyne,
UK) specific for BOND MAX autostainer having well standardized
protocol including all steps of routine immunohistochemistry.
Automated process selected into BOND MAX Autostainer performs
automated dewax for 30 min, incubation with primary antibodies as
it was described before, and then incubation with polymer for 30 min
followed by DAB chromogen for 10 min. Counterstain was the final
step automated immunostaining. Prostate tissue expressing CLIC1
was used as external positive control, and normal kidney tissue
adjacent to the tumor as internal positive control. A dark brown color
detected by microscopy on stained specimens having nuclear,
cytoplasmic and/or membranar pattern was considered as positive
for CLIC1. All immunohistochemical steps were fully automated and
controlled by the Bond Max autostainer (Leica Biosystems,
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Newcastle Upon Tyne, UK). The interpretation of immunostained
specimens included all three patterns: i) nuclear (N), ii) cytoplasmic
(C) and iii) membrane (M), but we also checked combined patterns:
i) all three (NMC), ii) nuclear and cytoplasmic (NC), iii) nuclear and
membranar (NM), iv) cytoplasmic and membrane (CM). We
stratified cases according to the ammounts of CLIC1 positive cells
as follows: i) low expressing tumors (10-30% of tumor cells
expressed CLIC1), ii) mild expressing tumors (30-50%) and iii) high
expressing tumors (>50% tumor cells positive for CLIC1). The
intensity of positive reaction was then assessed as: i) weak (1), ii)
moderate (2) and iii) strong (3).
Image aquisition and data analysis. All slides were scanned using
the Pannoramic Desk slide scanner (3D Histech, Budapest,
Hungary). Digital slides were stored in Case Center and were
assessed by using the Pannoramic Viewer Platform (3D Histech,
Budapest, Hungary). By using these methods we evaluated the
whole section of each specimen for CLIC1 expression pattern,
percentage of positive cells and CLIC1 signal intensity. Statistical
analysis was performedusing SPSS version 17, for evaluating
correlations tests (Pearson, Spearman and Kendall). A p-value less
than 0.05 being considered statistically significant. 
Results
The normal kidney tissue adjacent to the tumor presented a
heterogeneously positive reaction for CLIC1. The renal
cortex was intensely stained compared to the medulla. We
persistently detected CLIC1 expression inside the renal
corpuscle with a nuclear pattern restricted to podocytes. The
number of positive podocytes was significantly lower
compared to the presumed total number of podocytes in the
normal glomerulus. The tubular system of the normal kidney
had a different expression, the strongest immunostaining was
observed inside the proximal renal tubules compared to distal
and collecting tubes where a weak CLIC1 expression or
negative reaction was found (Figure 1).
Within the tumor tissue, CLIC1 was expressed in
malignant cells and in the endothelium of small intratumoral
and peritumoral blood vessels. CLIC1 showed high accuracy
in detecting locoregional and intravascular invasion thanks
to its high ability of intensively staining tumor cells, unlike
the staining of the surrounding tissues. Endothelial cells
lining some tumor capillaries expressed CLIC1 as well. 
CLIC1 was detected in 87.5% of all the examined cases
of cc RCC. Positive reaction was homogeneously distributed
in the whole tumor area in 31.42% of the total positive cases.
For the remaining cases (68.57%), positive tumor cells were
distributed in a “mosaic-like” fashion, with groups of
positive tumor cells intermingled within negative areas
(Figures 2A and B). 53.33% out of G2 cases and 91.66% of
G3 cases had a heterogeneous distribution of CLIC1
positivity. Heterogeneity of expression increased with tumor
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Figure 1. CLIC1 expression in the normal human renal parenchyma. Note the CLIC1 nuclear expression inside renal corpuscules (red arrow,
podocytes) and its cytoplasmic expression in the proximal renal tubules (red arrowhead). Immunohistochemistry for CLIC1, ×400 magnification.
grading, the most heterogeneous distribution of positive
reaction for CLIC1 observed for G3 tumors (Figure 3).
Based on this distribution pattern, we thought appropiate to
quantify the percent of positive cells from each case and we
found that 8.57% of all positive cases were CLIC1 low-
expressing tumors, 17.14% were CLIC1 mild-expression
tumors and 71.42% were CLIC1 high-expressing tumors.
The WHO/ISUP grading system was used to assess nuclear
and nucleolar features; in this classification, tumor grade is
assigned according to the highest grade cells present in the
tissue analyzed (27).
Following an initial evaluation regarding CLIC1
positivity/negativity in cc RCC, we distributed cases
depending on CLIC1 presence into i) nucleus (N), ii)
cytoplasm (C) and iii) membrane (M) of tumor cells. Few
cases had pure N, M, or C location of CLIC1 positive
expression, most of them displayed a combined pattern.
Thus, we defined 7 subgroups of cc RCC, three with single
expression N, M or C and four with a combined expression
as follows: iv) nuclear and cytoplasmic (NC), v) nuclear and
membrane (NM), vi) cytoplasmic and membrane (CM), and
vii) nuclear/membrane/cytoplasmic (NMC) (Figure 4). 
For G3 tumors, CLIC1 cytoplasmic expression was
strongly correlated with CLIC1 high-expressing tumors
(p=0.025) and also with tumor heterogeneity (p=0.004). No
G4 tumors were identified in the cases evaluated. 
By analyzing our results we observed a high and dynamic
heterogeneity of seven patterns related to tumor grade and
CLIC1 expressing pattern. We also observed that in tumours
with strong expression of CLIC1, the pattern of heterogeneity
significantly increased depending on G. Pure N pattern
(without any combination) was found only in CLIC1-high
expressing group, for G2 tumors. Pure C pattern was
persistently expressed for low-, mild- and high-subclasses,
but it gradually increased in high-expressing tumors. Another
important observation was that in the low-expressing group
the C pattern was related to G2, while in the high-expressing
group it was related to G3. Pure M pattern was observed only
in CLIC1-high expressing tumors related to G2. 
Assessement of combined patterns revealed that the NC
pattern was present in all three expressing groups, however,
it was most prominent in the high-expressing group. 
We found particular dynamics in the NM and CM patterns
within the group of high CLIC1-expressing tumors. NM
pattern gradually decreased from G1 to G3 tumors, while
CM pattern increased for G2 tumors compared to G1. Inside
G3 subgroup already containing NM and CM patterns it was
also observed the expression of NMC pattern which was not
observed in G1 and G2 subgroups of tumors with high
CLIC1 expression. 
Based on these evidences together with significant
correlations found between the parameters assessed in the
present study we may define four risk groups of cc RCC
depending on G, CLIC1 expression and pattern: i) G3/NM/low
CLIC1 expression (1), ii) G2/CM/mild CLIC1 expression (2),
iii) G1 or G2 /NM or CM /high CLIC1 expression (3) and iv)
G2/M /high CLIC1 expression (4) (Figure 5). 
Statistically significant correlations between the different
parameters used in the present study are summarized in
Table I. 
We also assessed the CLIC1 expression in relation to
TNM classification parameters. For cc RCC having a
combined nuclear and cytoplasmic CLIC1 expression, M
parameter was significantly correlated with G2 (p=0.045)
while N parameter showed a strong correlation with
percentage of CLIC1 positive tumor cells (p=0.008). For
concomitant nuclear and membranar CLIC1 expressing
tumors, we found that N parameter had three significant
correlations with G (p=0.039), the heterogeneity in CLIC1
expression (p=0.031) and the percentage of positive tumor
cells (p=0.026). An interesting difference has been found
between males and females regarding TNM parameters
CANCER GENOMICS & PROTEOMICS 16: 299-307 (2019)
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Figure 2. Homogeneous (A) versus heterogeneous (B) distribution of CLIC1 immunopositive reaction inside cc RCC (CLIC1 immunohistochemistry,
×40 magnification).
associated with CLIC1 expression. In males, T parameter
seems to significantly depend on the CLIC1 expression
pattern (p=0.014) and N parameter on the percentage of
positive tumor cells (p=0.043). No significant correlations
of TNM with other parameters used in the present study
were identified in the women’s group. 
Discussion
CLIC1 is known as „sensor and effector” of different cellular
processes involving the overproduction of reactive oxygen
species (ROS) in several benign (28, 29) and malignant
conditions (10, 11). Among malignant tumors, renal cell
carcinomas are well known as being highly ROS producing
tumors and this is strongly correlated with high tumor grade,
advance stage and metastatic behaviour (30). Based on these
data of high ROS production by RCC, already stated in the
literature and related with our results about CLIC1 expression,
we may speculate in this moment that the high expression of
CLIC1 certified here by our results may acts as sensor or
effector of cellular proliferation, invasion and metastasis. Also,
there is some experimental evidence supporting oxidative
stress inducing epigenetic changes in malignant renal cell lines
(31). Despite this evidence, the role of CLIC1 expression in
cc RCC has not been reported in the literature before. 
The present study examines for the first time the CLIC1
expression in cc RCC. Surprisingly, a high number of cc RCC
cases from our cohort showed CLIC1 positivity not only in
the malignant cells of the primary tumor, but also in the
neoplastic cells found in the surrounding connective tissue or
in blood vessels. It might be that the pattern of CLIC
expression is a useful tool for a better assessement of local and
vascular invasion in cc RCC, as it is able to detect, not only
groups of invasive cells, but also isolated cells spreading
around the tumor or invading tumor-associated blood vessels. 
The fact that CLIC1 is expressed in the nucleus,
cytoplasm and/or membrane of tumor cells suggests different
possible biological functions, depending on its location.
Usually, CLIC1 has a cytoplasmic localization in normal
human tissue and it translocates to the plasma membrane
during malignant transformation (32). Setti et al. have
proved that CLIC1 integration into the plasma membrane of
tumor cells induces a high tumorigenic potential of
glioblastoma cells. Also, CLIC1 is constitutively expressed
in the plasma membrane of stem/progenitor cells (32). Pure
M pattern appeared in our study only for ccRCC tumors
from high-CLIC1-expressing group with G2. High-
expressing group showed the highest heterogeneity regarding
the CLIC1 expression pattern, however, most of them were
defined by NM or CM pattern. A special attention should be
paid to those subgroups containing the M pattern. According
with Peretti et al., the fact that CLIC1 membrane expression
is crucial for cancer stem cells proliferation it may represent
a potential therapeutic target (14). In accordacne with this,
cc RCC subgroups with M pattern may be considered of high
risk. Our results support the existence of several cc RCC
subgroups, but the data are not yet sufficient to prove
whether CLIC1 overexpression may be considered as a
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Figure 3. CLIC1 heterogeneity expression according to tumor grade.
marker of aggresiveness. Further research should better
define these aspects in cc RCC, and assess whether there is
a possible role for CLIC1 as a marker for tumor risk
stratification.
Another important aspect of CLIC1 role is its possibile
involvement with tumor invasion and metastasis. We
observed in our study a strong CLIC1 expression in cc RCC
cancer cells invading surrounding tissues as well as in cells
detected in the lumen of tumor-associated blood vessels.
Moreover, focal areas of the strongest expression levels of
CLIC1 were also detected at the periphery of several cc RCC.
Gurski et al. have conducted the only study regarding CLIC1
expression in cancer cells derived from patients with
metastatic and localized kidney cancer (15). They proved that
CLIC1 translocation into the membrane acts as an activator
of invadopodia development and sustains metastatic potential
of cancer cells derived from kidney cancer. The same team
demonstrated that a similar mechanism may act also in
endothelial cells and promotes new blood vessel formation.
In our study we also observed several intratumoral and
peritumoral small blood vessels expressing CLIC1. This
aspect may be due to exosome-based exchange between
tumor cells and tumor microenvironment cells, such as
endothelial cells (33). Such a crosstalk could provide a route
responsible for vascular invasion and metastasis. Recently,
indeed, Thuringer et al. have reported this very crosstalk
between glioblastoma cells and endothelial cells that is
mediated by CLIC1 released through extracellular vesicles by
tumor cells and captured by endothelial cells, which are
induced to sprout and form tubes in 3D matrices (34). 
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Figure 4. Seven expression patterns of CLIC1 have been identified in ccRCC. (A) CLIC1-negative ccRCC (note that tumor blood vessels are CLIC1
positive). (B) Nuclear pattern (N), (C) cytoplasmic pattern (C), (D) membrane pattern (M), (E) nuclear/cytoplamic pattern (NC), (F) nuclear
membrane (NM), (G) cytoplasmic/membrane (CM) and (H) nuclear/ cytoplasmic/membrane pattern (NMC).
CLIC1 has already been reported as a potential biomarker
for some malignant tumors (6, 10, 16) and a potential
therapeutic target for new treatments in cancer. Its expression
in both tumor and endothelial cells may pave the way for the
development of future anti-CLIC1 therapy, able to target
both tumor and its associated vessels.
There are some data available concerning the inhibitory
effects of metformin (a well-known oral antidiabetic drug,
recently and intensely spotlighted as having anti-cancer effects
by suppressing oncogenic signaling pathways, including
receptor tyrosine kinase, PI3K/Akt, and mTOR pathways) on
CLIC1 expression in malignant tumors, especially against
Nesiu et al: CLIC1 Expression in Clear Renal Cell Carcinoma
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Table I. Correlations between CLIC1 parameters and tumor grade. All values highlighted in yellow support our results regarding the influence of
CLIC1 expression on tumor grade (G) and pattern heterogeneity.
                                                                                       G                                 HET                         Pattern                     Positivity                     Intensity
G                          Pearson’s Correlation                        1                                0.337*                       –0.348*                       –0.133                       –0.344*
                            Sig. (2-tailed)                                                                       0.017                          0.013                          0.358                          0.014
                            N                                                       50                                  50                               50                               50                                50
HET                     Pearson’s Correlation                   0.337*                                1                            –0.182                        –0.198                      –0.566**
                            Sig. (2-tailed)                                 0.017                                                                0.206                          0.167                          0.000
                            N                                                       50                                  50                               50                               50                                50
Pattern                  Pearson’s Correlation                  –0.348*                          –0.182                            1                              0.107                        0.437**
                            Sig. (2-tailed)                                 0.013                             0.206                                                             0.459                          0.001
                            N                                                       50                                  50                               50                               50                                50
Positivity             Pearson’s Correlation                   –0.133                           –0.198                         0.107                             1                            0.457**
                            Sig. (2-tailed)                                 0.358                             0.167                          0.459                                                             0.001
                            N                                                       50                                  50                               50                               50                               50
Intensity               Pearson’s Correlation                  –0.344*                        –0.566**                     0.437**                      0.457**                            1
                            Sig. (2-tailed)                                 0.014                             0.000                          0.001                          0.001                               
                            N                                                       50                                  50                               50                               50                               50
*Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed).
Figure 5. Cc RCC subgroups according to tumor grade (G), CLIC1 low, mild or strong expression and pattern as nuclear (N), cytoplasmic (C), membranar
(M), nuclear and cytoplasmic (NC), nuclear and membrane (NM), cytoplasmic and membrane (CM), and nuclear/membrane/cytoplasmic (NMC).
cancer stem cells (35). Among all the different mechanisms
proposed for metformin-mediated antiproliferative activity
there is also the inhibition of CLIC1 activity. Gastric cancer
cell lines SGC-7901 and MGC-803 express CLIC1 (36). The
specific inhibitor indanyloxyacetic acid-94 (IAA94) prevents
CLIC1 from translocating in the cell membrane and through
this action it prevents cell aggregation and proliferation (37).
Silencing of the CLIC1 promotes apoptosis and decreases
gallbladder cancer cells proliferation and migration (38). 
In this study we report, for the first time, the expression
and histopathological significance of CLIC1 in human cc
RCC specimens, as detected by immunohistochemistry.
CLIC1 expression stratified cc RCC in four subgroups
depending on tumor grade, CLIC1 expression pattern and
percent of tumor-positive cells. Further investigations are
needed to elucidate the prognostic and therapeutic impact of
CLIC1in cc RCC.
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